244 results
8-K
CYCC
Cyclacel Pharmaceuticals Inc
22 Mar 12
Cyclacel Announces $3.0 Million Financing to Fund Ongoing Litigation Expenses
12:00am
existing institutional stockholders (the “Investors”) and raised gross proceeds of $3,036,000 to fund certain litigation-related expenses on certain … intellectual property (the “Litigation”) and otherwise for general corporate purposes. Under the terms of the Agreement, the Investors purchased 4,688,079
8-K
EX-99.1
CYCC
Cyclacel Pharmaceuticals Inc
4 Apr 13
Other Events
12:00am
CLAIMS IN THEIR PATENT LITIGATION
Berkeley Heights, NJ, April 4, 2013 – Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) (NASDAQ: CYCCP) (“Cyclacel … .
As a result, the litigation between Cyclacel and Celgene in the United States District Court for the District of Delaware, case number 1:10-cv-00348-GMS
424B3
CYCC
Cyclacel Pharmaceuticals Inc
16 May 12
Prospectus supplement
12:00am
will be used to fund ongoing litigation-related expenses involving specified Cyclacel intellectual property and for general corporate purposes.
Under … equal to 10% of any future litigation settlement related to the specified intellectual property, subject to a cap. In certain defined situations
8-K
EX-99.1
rbgcpa akjb49
22 Mar 12
Cyclacel Announces $3.0 Million Financing to Fund Ongoing Litigation Expenses
12:00am
424B3
q4l7l
16 May 12
Prospectus supplement
12:00am
424B3
2yd2zh z036qbz
16 May 12
Prospectus supplement
12:00am
424B3
8mej0p77
16 May 12
Prospectus supplement
12:00am
424B3
gdc 49vv8
15 Aug 12
Prospectus supplement
12:00am
8-K
7f4oo9rxh p6039trpm7
4 Apr 13
Other Events
12:00am
424B3
xkpy7whk9
16 Nov 12
Prospectus supplement
12:00am
424B3
8vrmda
16 Nov 12
Prospectus supplement
12:00am
424B3
wyqr r9armo
15 Aug 12
Prospectus supplement
12:00am